Skip to main content
. 2021 Jan 11;22(2):89–105. doi: 10.1080/15384047.2020.1868937

Figure 1.

Figure 1.

FDA-approved drugs in advanced ovarian cancer

dMMR: deficient mismatch repair, FDA: US Food and Drug Administration, HRD: homologous recombination deficiency, L: line of treatment, MSI: microsatellite instability high, mut: mutated, PlSOC: platinum-sensitive ovarian cancer, PlROC: platinum-resistant ovarian cancer, PLD: pegylated liposomal doxorubicin.